Tikvah K Hayes, Elisa Aquilanti, Nicole S Persky, Xiaoping Yang, Erica E Kim, Lisa Brenan, Amy B Goodale, Douglas Alan, Ted Sharpe, Robert E Shue, Lindsay Westlake, Lior Golomb, Brianna R Silverman, Myshal D Morris, Ty Running Fisher, Eden Beyene, Yvonne Y Li, Andrew D Cherniack, Federica Piccioni, J Kevin Hicks, Andrew S Chi, Daniel P Cahill, Jorg Dietrich, Tracy T Batchelor, David E Root, Cory M Johannessen, Matthew Meyerson
The epidermal growth factor receptor, EGFR, is frequently activated in lung cancer and glioblastoma by genomic alterations including missense mutations. The different mutation spectra in these diseases are reflected in divergent responses to EGFR inhibition: significant patient benefit in lung cancer, but limited in glioblastoma. Here, we report a comprehensive mutational analysis of EGFR function. We perform saturation mutagenesis of EGFR and assess function of ~22,500 variants in a human EGFR-dependent lung cancer cell line...
March 28, 2024: Nature Communications